KalshiNew Jersey's Drug-Industry Payrolls Have Not Touched the Bar Once in 2026
The New Jersey pharmaceutical jobs odds for 2026 rest on eight months of federal data that never once reached the bar: the contract asks whether the state's pharmaceutical and medicine manufacturing employment will average more than 30,300 jobs in 2026, and every monthly reading from January to August came in below that. The market treats a year-over-year rise as a long shot for that reason. It is a New Jersey question by its own title, settled on a Bureau of Labor Statistics series for the state's drug makers. Kalshi is the only exchange pricing this contract, and the live board above carries its current price.
What the New Jersey Pharmaceutical Jobs Market Is Asking
The question is narrow and exact. Kalshi's contract pays Yes if the Bureau of Labor Statistics reports that New Jersey's annual-average employment in Pharmaceutical and Medicine Manufacturing for 2026 is above 30,300. The underlying is BLS series SMU34000003232540001, all employees in that industry in New Jersey, from the Current Employment Statistics survey, measured in thousands and not seasonally adjusted. The 30.3 thousand line is the series' 2025 annual average, which is why the exchange titles the market as a question about jobs rising year over year, and Kalshi's rules say the line is fixed even if BLS later revises its 2025 value.
The contract is therefore not about whether the industry is growing in the abstract. It is about one published number, the 2026 annual average of a single state series, against one fixed threshold.
Why the New Jersey Pharmaceutical Jobs Price Sits Low
What the price is saying is that the year is already most of the way to a No. Kalshi had Yes at 9% on October 12, 2026, the same price it has shown since October 1, which means the market treats a rise above 30,300 as roughly a one-in-eleven outcome, and the BLS series shows why.
The 2026 readings, in thousands, were 29.5 in January, 29.6 in February, 29.3 in March, 29.2 in April, 29.4 in May, 29.5 in June, 29.6 in July and 29.5 in August, the last of them marked preliminary. The highest of the eight is 29.6. None is within 0.6 thousand of the threshold. Taken together the eight months sum to 235.6 thousand job-months, so for the annual average to finish above 30.3, September through December would have to average above 32.0 thousand. The series has not printed a month that high in any reading from January 2015 through August 2026; its peak in that span was 31.2 thousand, in July and August of 2024.
The trend behind those numbers runs the same way, after a long climb. The industry employed about 25 thousand people in New Jersey through the second half of the 2010s, with annual averages between 24.9 and 25.5 thousand from 2015 to 2020. Then it grew for four straight years, to 26.3 thousand in 2021, 28.2 thousand in 2022, 29.8 thousand in 2023 and a peak annual average of 30.8 thousand in 2024. The 2025 average of 30.3 thousand was the first annual decline in that run. Inside 2025 it drifted down almost every month, from 30.7 in January to 29.7 in November and 29.9 in December, so the 2025 average that set the bar was itself built on a falling line. The 2026 months picked up where December left off rather than where the 2025 average sat.
That is the structural read: a year-over-year rise is priced low because the year-to-date data sit nearly a thousand jobs under the line and the remaining months would need to set a level the series has never reached in more than a decade of readings.
New Jersey's Pharmaceutical Jobs in the Wider Labour Market
The drug industry's slide is not the state's labour market as a whole. BLS counted 4,356.4 thousand nonfarm jobs in New Jersey in August 2026 on a preliminary basis, against 4,351.6 thousand in August 2025, a slight rise. Manufacturing overall was softer: 250.5 thousand in August 2026, preliminary, against a 2025 annual average of 252.0 thousand, with the 2026 months ranging from 247.1 to 250.5. Pharmaceutical and medicine manufacturing was about 29.5 thousand of that August total, close to one manufacturing job in eight in the state.
That share is the reason the exchange wrote a New Jersey contract on this industry at all, and the reason a reader in the state has a stake in it: the contract is a readout on one of the state's signature employers, measured on the federal government's own monthly survey.
The Case Against the New Jersey Pharmaceutical Jobs Read
The strongest case against the read is that the numbers on the page today are not the numbers that settle the contract. Every 2026 figure in the series is an estimate from a monthly survey of employers, and the August reading is marked preliminary. Kalshi's own rules anticipate that BLS revises the series, by fixing the threshold at 30.3 thousand even if the 2025 value changes, and the contract does not close until April 30, 2027, after months of further releases. A reader who holds this view sees a 2026 annual average that could be restated upward when the survey is checked against fuller records, and a 9% price on Kalshi on October 12, 2026 as too low for a contract that settles on a revised number rather than today's.
The counterpoint is the size of the gap. A revision would have to lift the whole year by close to a thousand jobs to clear the line, not nudge a single month.
The board itself is a reason for care in both directions. Total volume on the contract was $12.8K on October 12, 2026, $2 more than on October 5, and Kalshi's quote has held at 9% since October 1, 2026, so the figure reflects a handful of trades rather than a deep market. A thin board can sit still through a data release that should have moved it, or move sharply on a single order.
What Changes the New Jersey Pharmaceutical Jobs Read
The read is wrong if the autumn readings jump toward 32 thousand or a revision lifts the earlier 2026 months well above 29.6 thousand.
• The September 2026 state employment release: the first of the four remaining monthly readings, and the next revision to August's preliminary 29.5.
• The October and November 2026 releases: each one either narrows the distance to 30.3 or confirms that the remaining months cannot close it.
• The December 2026 reading and the 2026 annual average: the number that settles the contract, published in BLS's state series before the April 30, 2027 close.
• Any revision to the 2026 months: a restatement of January to August would move the starting point for every later calculation.
When the New Jersey Pharmaceutical Jobs Market Resolves
Kalshi resolves on the 2026 annual average BLS reports for series SMU34000003232540001, not seasonally adjusted, against a fixed 30,300 threshold. The contract closes early if the data is released, and otherwise closes on April 30, 2027 and expires on May 7, 2027.
Related New Jersey Markets Beyond Pharmaceutical Jobs
The state's economic contracts are gathered on the money page, and the full list of New Jersey markets, from the Senate race to the Devils, is on the markets page. For a race where jobs and the economy are on the ballot, the New Jersey Senate market covers the November 3, 2026 election.
